____________________________________
Industrial Liaison Group:
Tel: +44 (0) 1235 778797
E-mail: [email protected]
The global rise of antibiotic-resistant pathogens poses a significant challenge to modern medicine. Staphylococcus aureus, a notorious bacterium, is responsible for a spectrum of health issues ranging from minor skin infections like impetigo and cellulitis to severe, life-threatening conditions such as pneumonia and sepsis. Its ability to deploy multiple virulence factors makes it difficult to target with vaccines or monoclonal therapies1.
To address this, Janssen Research & Development used Diamond’s I24-Microfocus Macromolecular Crystallography beamline to determine the atomic structure and interactions of SM1B74, a human-derived monoclonal antibody fused with centyrin moieties2. This crucial study revealed how SM1B74 binds to bacterial targets and neutralises toxins, guiding the design and optimisation of mAbtyrin treatments to effectively combat S. aureus infections.
1Lab-made molecules called monoclonal antibodies (mAbs) to treat various diseases
2 These centyrin moieties are small, engineered protein segments derived from a human protein called Tenascin C. They have exceptional stability, strong binding capabilities, and high specificity.
Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.
Copyright © 2022 Diamond Light Source
Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE
Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd
Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.